In the other two cases of ALK fusion gastric cancer, one with RAB10–ALK mutation refused off-label use of agents such as crizotinib and ceritinib, and the other patient with ALK–HMBOX fusion received alectinib as first-line targeted therapy and achieved complete response (CR) in thoracic and cervical metastatic lymph nodes and PR in brain metastases, which reached a 6-month PFS. This evidence concerns the gene ALK and gastric cancer.